ChemPartner
22.12.2023 22:02:41 CET | ACCESS Newswire | Press release
Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs
SHANGHAI, CHINA / ACCESSWIRE / December 22, 2023 / ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database. This innovative platform serves as a centralized hub, empowering ChemPartner's clientele with seamless access to a wealth of information on the organization's cutting-edge preclinical platforms. The database includes 800+ tumor models, 30+ cancer types, 20,000 genes, 2,300+ pathways, 1,800 SoC data from literature (500 internal), and 30+ analytic modules.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Screenshot of the online Biology Database from ChemPartner
ChemPartner's renowned biology and pharmacology department, known for its vanguard oncology, immunology, CNS, and metabolic services, has curated an extensive collection of in vitro and in vivo models. The database boasts over 2,000 biochemistry assays, 800 cell lines, 500 patient-derived xenograft (PDX) models, 350 cell-derived xenograft (CDX) models, and 50 syngeneic models. Each model is meticulously characterized with comprehensive data encompassing genomics, pharmacology, histopathology, and relevant clinical information.
Cell Line Models - ChemPartner Biology Database
To ensure a smooth and efficient rollout of this substantial volume of data, the database will be introduced in stages. We are delighted to announce that the first stage, featuring cell line data, is now live on https://database.chempartner.com. Subsequent stages will include CDX, syngeneic, and PDX models, followed by biochemistry data.
The Biology Database, a flagship online collaborative platform, prominently features the Tumor Model Database. This revolutionary resource offers an array of features, including:
- Unified Data Hub: Integration of dispersed tumor model data into a centralized database for efficient management and retrieval, simplifying user access to diverse tumor models.
- Detailed Annotations: Each model is accompanied by intricate annotations including genomics, pathology, and pharmacology data, enabling rapid understanding of model characteristics and suitability for specific research needs.
- Rapid Search and Filtering: Multidimensional search and filtering capabilities empower researchers to swiftly locate models based on cancer type, genomic features, drug sensitivity, and more.
- Data Analysis and Mining: Robust tools facilitate tasks like drug mechanism analysis and biomarker discovery through differential gene expression and drug sensitivity analyses, supporting informed research decisions.
- Data Visualization: Intuitive charts, statistics, and visualization tools present complex data clearly and concisely, aiding in model selection and analysis.
Dr. Lilly Xu, President of Shanghai ChemPartner, expressed enthusiasm about the launch saying, "We are excited to provide our customers with access to this powerful new resource. This comprehensive database will make it easier for our customers to find and use the right models for their research, propelling drug development towards new heights with better precision, efficacy, and efficiency."
-
About ChemPartner
ChemPartner is a leading global CRO and CDMO providing drug discovery, development, and manufacturing services to the pharmaceutical and biotechnology industries. With a team of over 2,000 scientists across multiple countries, ChemPartner offers a comprehensive range of services including preclinical pharmacology, toxicology, drug metabolism and pharmacokinetics, chemistry development, and biologics development. For more information, please visit https://chempartner.com and connect with ChemPartner on LinkedIn, X, and YouTube.
Contact Information
Sarah Stapleton
Marketing Director
news@chempartner.com
6504199974
Related Images
|
SOURCE: ChemPartner
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OMP Extends UnisonIQ with Agent Library and Agent Studio: AI Agents that Produce Executable Supply Chain Plans3.11.2026 15:00:00 CET | Press release
ANTWERPEN, BE / ACCESS Newswire / November 3, 2026 / OMP, a leader in supply chain orchestration, today extended UnisonIQ, the AI framework in its Unison Planning™ platform, with the Agent Library of ready-to-deploy AI agents and Agent Studio, where companies build their own. The agents run on the optimization engines in Unison Planning™ and produce executable supply chain plans. Bekaert is among the early adopters of UnisonIQ. Supply chain organizations face board-level pressure to show progress on AI, but many struggle to move beyond experiments. Generic AI models and decision-intelligence tools miss the industry-specific context and semantics that planning depends on, while planning tools with an AI layer on top lack reasoning depth. Both can produce a confident answer that ignores real-world constraints such as shelf life, co-products, and shared capacity. In UnisonIQ, by contrast, each agent works from a reality-based digital twin of the customer's own supply chain and calls on th
Fermi Provides Update on Lease Agreement as Parties Work Toward Closing3.11.2026 13:00:00 CET | Press release
DALLAS, TX / ACCESS Newswire / November 3, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today issued the following statement on the Data Center Lease and Services Agreement (the "Lease") between its wholly owned subsidiary, Fermi Campus 1 LLC, and TensorWave TEX1, LLC ("TensorWave"), after the October 31, 2026 closing date passed without extension. "Both Fermi and TensorWave remain committed to this lease, and we are continuing to work through the remaining conditions prior to close," said Lee McIntire, Fermi Chief Executive Officer. "We expect to provide more information on the discussions during our earnings call next week, or sooner if appropriate." The Lease, signed in August 2026, provides that its effectiveness is subject to the satisfaction or waiver of specified closing conditions. Those conditions include executing and delivering related work letters and guaranties; finalizing operations schedules and a service-level agreem
IXOPAY Announces IXO One, a Modular Payments Platform Built for an Era of Fluid Commerce3.11.2026 10:00:00 CET | Press release
DALLAS, TX / ACCESS Newswire / November 3, 2026 / IXOPAY, the leader in payment infrastructure enabling fluid commerce, today announced the launch of IXO One, an AI-native, modular payment platform that unifies orchestration, payments intelligence, and tokenization. It gives merchants the flexibility to buy what they need, build what they want, and adapt as commerce evolves. Built to power an era of fluid commerce and technology-driven payment experiences, IXO One provides the dynamic infrastructure needed to adapt quickly without ripping out or replacing their current payment stack. Traditional payment infrastructure makes it difficult for merchants to embrace fluid commerce and a rapidly changing payment market. From fragmented systems to rigid provider relationships, a new opportunity can require a heavy integration lift, slow time-to-market, and increased costs. IXO One's modular platform helps merchants mitigate the payment friction that leads to provider dependency, expensive mig
Chervon Promotes Soobia Haroon to Vice President, Human Resources - NA2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Chervon promotes Soobia Haroon to Vice President, Human Resources - NA, effective November 2, 2026, reporting to Joe Galli, CEO. Over the past two years, Haroon has been a key member of the Chervon Senior Executive Team, driving talent acquisition, organizational development, and transformation. She has provided strategic leadership across all HR functions while strengthening corporate HR strategy, governance, and processes to support the company's objectives and continued growth. Before joining Chervon, Soobia progressed through a series of human resources positions at several multinational companies. Her HR experience is strong in supporting many functional areas, including supply chain, distribution, manufacturing, IT, engineering, product management, marketing, and finance. "Soobia has been instrumental in our aggressive talent acquisition initiative since I joined Chervon," said Joe Galli. "Her extensive HR experience, her sens
Chervon Names Thomas Scherer Vice President of Organizational Development - Sales, End User Marketing, and Service2.11.2026 15:00:00 CET | Press release
NAPERVILLE, IL / ACCESS Newswire / November 2, 2026 / Chervon names Thomas Scherer Vice President of Organizational Development - Sales, End User Marketing, and Service, effective November 2, 2026, reporting to Matt DeFeo, SVP, Sales, Training, and Recruiting. Scherer brings to Chervon extensive organizational development experience supporting the build-out of large-scale sales teams and end user marketing teams. He is highly experienced in managing employment law, compliance, employee relations, compensation, workforce analytics, training, recruiting, and career development. His world class organizational development skills will be invaluable as the company develops the very best sales, store coverage, end user marketing, and after-sales service teams. Most recently, Tom was Vice President of Human Resources for TTI/Milwaukee where he was responsible for HR and organizational development for a 2000+ person field sales team. Previously, Scherer advanced through a series of HR, training
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom